Mucomycoses identified using the COVID-19 health impacts with mucomycoses consider the COVID-19
A multi-center study
Keywords:
identified, mucomycoses, COVID-19, health impactsAbstract
Objective: The study's participants had mucormycosis associated with the coronavirus disease 2019 (COVID-19), and the researchers sought to describe their clinical characteristics, risk factors, and ultimate findings (CAM). Study Design: A Multi-center Study. Place and Duration: NTH AND HMC hospital Peshawar. Duration July 2019 to July 2020. Methods: Overall, this research included 180 cases in which both sexes showed signs of mucormycosis during the pandemic coronavirus outbreak of 2016. Patients were between the ages of 22 and 80. After obtaining written permission from each patient, demographic information such as age, sex, BMI, and illness duration was gathered. Patients were hospitalized in COVID-19 emergency ward and underwent RT-PCR and MRIs. Mucormycosis was examined for its comorbidities, symptoms, and etiology. End-of-study death rates, hospitalizations, and admissions to intensive care units were all tallied up. To analyze the complete dataset, the SPSS 20.0 version was used. Result: There were 130 men and 50 females in the study population (26.6 percent ). The patients had a mean age of 52.44 years and a mean BMI of 27.74 kg/m2. In this research, 54 (62.2 percent) patients had COVID-19, and 35 (38.9 percent) had coronavirus.
Downloads
References
Al Mutair A, Alhumaid S, Alhuqbani WN, Zaidi ARZ, Alkoraisi S, Al-Subaie MF,et al. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study. Eur J Med Res.2020;25:61.
Alisha JM, Alhajjaj AH, Alkhabbaz FL, AlAbduljabar TH, Alsaif A, Alsaif H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients inthe Eastern Province of Saudi Arabia. J Infect Public Health. 2021;14:6–11.
Al-Omari A, Alhuqbani WN, Zaidi ARZ, Al-Subaie MF, AlHindi AM, Abogosh AK, et al. Clinical characteristics of non-intensive care unit COVID-19 patients inSaudi Arabia: a descriptive cross-sectional study. J Infect Public Health. 2020;13:1639–44.
Alsuwaida K. Primary cutaneous mucormycosis complicates the use of adhesivetape to secure the endotracheal tube. Can J Anesth. 2002;49:880–
Al-Tawfiq, J.A., Alhumaid, S., Alshukairi, A.N. et al. COVID- And mucormycosis superinfection: the perfect storm. Infection (2021).
Arjun R, Felix V, Niyas VKM, Kumar MAS, Krishnan RB, Mohan V, et al. COVID-19 associated rhino-orbital mucormycosis: a single center experience often cases. QJM An Int J Med. 2021
Bahrani S, Al-Tawfiq JA, Jebakumar AZ, Alghamdi M, Zakary N, Seria M, et al. Clinical features and outcome of low and high corticosteroids in admitted COVID-19 patients. J Epidemiol Glob Health. 2021
Chander J, Kaur M, Singla N, Punia RPS, Singhal SK, Attri AK, et al. Mucormycosis: battle with the deadly enemy over five years in India. J Fungi 2018;4:46.
Cheng S, Zhao Y, Wang F, Chen Y, Kaminga AC, Xu H. Comorbidities' potentialimpacts on severe and non-severe patients with COVID-19: A systematic review and meta- analysis. Medicine (Baltimore). 2021;100:e24971.
Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. Medicine. 2019;55:1–14.
Giri M, Puri A, Wang T, Guo S. Comparison of clinical manifestations, pre- existing comorbidities, complications and treatment modalities in severe and non-severe COVID- 19 patients: a systemic review and meta-analysis. Sci Prog. 2021.
Hartnett KP, Jackson BR, Perkins KM, Glowicz J, Kerins JL, Black SR, et al. A guide to investigating suspected outbreaks of mucormycosis in healthcare. J Fungi.2019;5:69.
Hoang K., Abdo T., Reinersman J.M., Lu R., Higuita N.I.A. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well- controlled diabetic patient. Med Mycol Case Rep. 2020;29(1):22–24.
Jeong W., Keighley C., Wolfe R. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26–34.
Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS ONE. 2021.
Lionakis M.S., Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828–1838.
Maartens G., Wood M.J. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother. 1991;28(13–22):17–44.
Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID- 19: a cross-sectional descriptive multicenter study from Iran. Mycoses. 2021.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, SchaufeleRL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reportedcases. Clin Infect Dis 2005; 41:634–53
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematicreview of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.
Skoda A., Pagano L., Groll A. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin MicrobiolInfect. 2011;17(12):1859–1867.
Zurl C., Hoenigl M., Schulz E. Autopsy proved pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel). 2021 Jan 27;7(2):88.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
